Brucella CRISPR (clustered regularly interspaced short palindromic repeats) nucleic acid visual detection kit and application
Through the nucleic acid visual detection kit of the RPA-CRISPR/Gs12-7 system, combined with RPA primers and crRNA, the rapid, sensitive and high specific detection of nucleic acids of Brucella genomics is achieved, and the detection cost in the existing technology is solved. The problem of insufficient sensitivity provides a low-cost and efficient detection solution.
Patent Information
- Application Number
- CN202411077113.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-08
AI Technical Summary
The existing Brucella laboratory detection methods require expensive instruments and strict laboratory conditions, which limit their application, and are insufficient in sensitivity and specificity, making it difficult to quickly detect Brucella genomic nucleic acids.
The nucleic acid visual detection kit based on the RPA-CRISPR/Gs12-7 system was used to detect Brucella genomic nucleic acid by RPA primers and crRNA binding to Cas12a enzyme cleavage reaction, and fluorescent signals were used to detect Brucella genomic nucleic acids, achieving rapid, sensitive and highly specific detection.
A method that can quickly, sensitively and specifically detect Brucella genomic nucleic acids has been developed, which reduces the detection cost and laboratory conditions requirements, and has high application value and accuracy.
Smart Images

Figure CN118910293A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of microbial detection, and in particular relates to a CRISPR nucleic acid visualization detection kit for Bacillus ruxiformis and its application. Background Art
[0002] At present, the laboratory detection methods for Brucella in my country mainly include molecular biology techniques, and the molecular biology detection methods mainly use polymerase chain reaction (PCR) technology. Real-time fluorescence PCR, which has been developed in recent years, can achieve closed-tube detection by adding SYBR Green I fluorescent dye or a specific TaqMan fluorescent probe to the reaction system. It not only maintains the sensitivity and other characteristics of traditional PCR technology, but also avoids false positive contamination and shortens the detection time.
[0003] However, the PCR method requires expensive instruments and strict laboratory conditions, which limits its application. Summary of the invention
[0004] In view of this, the present invention provides a Brucella CRISPR nucleic acid visualization detection kit and application. The technology of the present invention can detect Brucella genomic nucleic acid rapidly, sensitively and highly specifically, and has great application value.
[0005] In order to achieve the above object, the present invention adopts the following technical solutions:
[0006] In a first aspect, the present invention provides a Brucella CRISPR nucleic acid visualization detection kit, comprising RPA primers, wherein the RPA primers include F and R, the nucleotide sequence of F is shown in SEQ ID NO.21; the nucleotide sequence of R is shown in SEQ ID NO.22.
[0007] Preferably, it also includes crRNA, and the nucleotide sequence of the crRNA is shown in SEQ ID NO.14.
[0008] Preferably, the crRNA is used to target the BCSP31 gene, and the nucleotide sequence of the BCSP31 is shown in SEQ ID NO.16.
[0009] In a second aspect, the present invention provides a use of the kit in detecting Brucella for non-diagnostic purposes.
[0010] Finally, the present invention provides a method for detecting Brucella using the kit for non-diagnosis purposes, comprising the following steps:
[0011] S1. Obtain Brucella nucleic acid template;
[0012] S2, amplifying the Brucella nucleic acid template to obtain an amplified product;
[0013] S3, subjecting the amplified product to a restriction digestion reaction with the homologous protein Gs12-7 of Cas12a to obtain a restriction digestion product;
[0014] S4. Detect the enzyme cleavage product under blue light, ultraviolet light and microplate reader; when there is a fluorescent signal under the blue light and ultraviolet light, and the fluorescence value detected by the microplate reader is greater than 1488, the test result is positive; when there is no fluorescent signal under the blue light and ultraviolet light, and the fluorescence value detected by the microplate reader is less than 1488, the test result is negative.
[0015] It should be noted that a positive result means that Brucella nucleic acid is detected, and a negative result means that Brucella nucleic acid is not detected.
[0016] Preferably, in step S1, the specific steps of obtaining the Brucella nucleic acid template are: mixing the sheep blood and the crude extract, heating them, centrifuging them and taking the supernatant for preservation.
[0017] Preferably, the heating conditions are first heating at 65°C for 5 min, and then heating at 95°C for 5 min.
[0018] Preferably, the centrifugation condition is a rotation speed of 12000 rpm and a centrifugation time of 2 min.
[0019] Preferably, in step S2, the Brucella nucleic acid template is amplified using an amplification system, the volume of the amplification system is 50 μL, and the amplification system comprises: A basic reaction tube (Twist Dx), 29.5 μL Buffer, 2.5 μL MgSO4, 2.4 μL primer F, 2.4 μL primer R, 2.5 μL Brucella nucleic acid template, and add nuclease-free water to 50 μL.
[0020] Preferably, in step S3, the reaction system of the enzyme cleavage reaction includes: 1 μM purified crRNA targeting Brucella nucleic acid gene, 2.5 μL of the amplification product, 0.5 μM Cas12a, 1 μM ssDNA-FQ reporter (ROX-N12-BHQ2), 2 μL 10xNEB rCutSmart buffer, and the reaction system is supplemented to 20 μL with nuclease-free water.
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] (1) The present invention provides a brucellosis nucleic acid visualization detection technology based on the RPA-CRISPR / Gs12-7 system. By combining RPA technology with CRISPR / Gs12-7 detection and using a double-labeled fluorescent gene for nucleic acid fluorescence visualization detection, a detection method for Brucella genomic nucleic acid that can be rapidly, sensitively, and highly specific has been developed, which has great application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 A flow chart of sheep blood collection, processing and detection provided in Example 1 of the present invention;
[0024] Figure 2 The gel electrophoresis diagram of Gs12-7 endonuclease provided in Example 1 of the present invention;
[0025] Figure 3 This is a fluorescence signal diagram of crRNA provided in Example 1 of the present invention;
[0026] Figure 4 This is a fluorescence signal diagram of the BCSP31 gene fragment plasmid provided in Example 1 of the present invention;
[0027] Figure 5 This is a gel electrophoresis diagram of the DNA product of the BCSP31 gene amplified by RPA provided in Example 2 of the present invention;
[0028] Figure 6 This is a fluorescence visualization detection diagram of the RPA amplification product provided in Example 2 of the present invention;
[0029] Figure 7 A fluorescence signal diagram of a multifunctional microplate reader of the RPA amplification product provided in Example 2 of the present invention;
[0030] Figure 8 This is a gel electrophoresis diagram of the DNA product of the BCSP31 gene amplified by RPA provided in Example 3 of the present invention;
[0031] Fig. 9 This is a fluorescence visualization detection diagram of the RPA amplification product provided in Example 3 of the present invention;
[0032] Fig.10 A fluorescence signal diagram of a multifunctional microplate reader of the RPA amplification product provided in Example 3 of the present invention;
[0033] Fig.11 This is a gel electrophoresis diagram of the product of RPA amplification of the BCSP31 gene provided in Example 4 of the present invention;
[0034] Fig.12 This is a fluorescence visualization detection diagram of the RPA amplification product provided in Example 4 of the present invention;
[0035] Fig.13 A fluorescence signal diagram of a multifunctional microplate reader of the RPA amplification product provided in Example 4 of the present invention;
[0036] Fig.14 This is a fluorescence visualization detection diagram of the RPA amplification product provided in Example 5 of the present invention;
[0037] Fig.15 A fluorescence signal diagram of a multifunctional microplate reader of the CRISPR / Gs12-7 enzyme digestion product provided in Example 5 of the present invention;
[0038] Fig.16 The known concentration (6.02×10 9 copies / μL-6.02×10 1 The plasmid containing Brucella BCSP31 gene fragment was used for qPCR detection to prepare the standard curve, and the supernatant after lysis treatment was used for qPCR detection and copy number calculation.
[0039] Fig.17 This is a qPCR amplification curve diagram of the standard sample and simulated clinical sample provided in Example 5 of the present invention.
[0040] Note: Figure 3 In the figure, PC represents the complementary single-stranded DNA molecule of crRNA, i.e., ssDNA activator, without PAM; "+" represents the amplified product of BCSP31 gene; "-" represents the non-template negative control, among which BCSP-crRNA-TTTV-1, BCSP-crRNA-TTTV-2, BCSP-crRNA-TTTV-3, BCSP-crRNA-TTTV-4, BCSP-crRNA-CTTV-1, BCSP-crRNA-GTTV-1, and BCSP-crRNA-ATTV-1 can target the amplified fragment of BCSP31 gene;
[0041] Figure 5 Lane 1: 500 DNA Maker; Lane 2: Primer 1, 6.02×10 4 copies / μL; Lane 3: Primer 1, 6.02×10 1 copies / μL; Lane 4: Primer 1, 6.02×10 0 copies / μL; Lane 5: Primer 1, non-template control group; Lane 6: Primer 2, 6.02×10 4 copies / μL; Lane 7: Primer 2, 6.02×10 1copies / μL; Lane 8: Primer 2, 6.02×10 0 copies / μL; Lane 9: Primer 2, non-template control group; Lane 10: Primer 3, 6.02×10 4 copies / μL; Lane 11: Primer 3, 6.02×10 1 copies / μL; Lane 12: Primer 3, 6.02×10 0 copies / μL; Lane 13: Primer 3, non-template control group;
[0042] Figure 6 In the table, Blue Light refers to the pictures taken with a mobile phone in a blue light gel cutting instrument; UV Light refers to the pictures taken with a mobile phone in a UV gel imaging system;
[0043] Figure 8 Middle, lane 1: 500 DNA Maker; lane 2: 6.02 × 10 9 copies / μL; Lane 3: 6.02×10 8 copies / μL; Lane 4: 6.02×10 7 copies / μL; Lane 5: 6.02×10 6 copies / μL; Lane 6: 6.02×10 5 copies / μL; Lane 7: 6.02×10 4 copies / μL; Lane 8: 6.02×10 3 copies / μL; Lane 9: 6.02×10 2 copies / μL; Lane 10: 6.02×10 1 copies / μL; Lane 11: 6.02×10 0 copies / μL; Lane 12: 6.02×10 -1 copies / μL; Lane 13: non-template control group;
[0044] Fig. 9 , 12 , 13, Blue Light refers to the pictures taken with a mobile phone in a blue light gel cutting instrument; UV Light refers to the pictures taken with a mobile phone in a UV gel imaging system;
[0045] Fig.16 In the experiment, the concentration of known 9 copies / μL-6.02×10 1The plasmid containing the Brucella BCSP31 gene fragment was used for qPCR detection to prepare a red standard curve; the supernatant after lysis treatment was tested by qPCR and the copy number was calculated and represented in green in the figure;
[0046] Fig.17 In the figure, the amplification curve of the standard sample qPCR detection is the figure on the left, and the amplification curve of the simulated clinical sample qPCR detection is the figure on the right. DETAILED DESCRIPTION
[0047] The present invention is further described in detail below in conjunction with specific embodiments so that those skilled in the art can understand the present invention more clearly.
[0048] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific embodiments of the present invention are described in detail below in conjunction with the accompanying drawings. In the following description, many specific details are set forth to facilitate a full understanding of the present invention. However, the present invention can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without violating the connotation of the present invention, so the present invention is not limited by the specific implementation disclosed below.
[0049] Terminology
[0050] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0051] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".
[0052] The term "CRISPR / Gs12-7 nucleic acid detection" refers to the technology of using CRISPR / Gs12-7 to specifically identify and cut the target gene, and non-specifically cut the ssDNA fluorescent reporter gene, and detect the target nucleic acid molecule with the help of a fluorescent signal detection system. This technology comes from the disclosed invention patent "Thermostable nuclease and its mediated gene editing system (ZL202310086152.7).
[0053] The term "Gs12-7" refers to an endonuclease in the CRISPR / Cas12a system, characterized by having both cis and trans single-stranded DNA cleavage activities. The high activity of Gs12-7 is very suitable for rapid nucleic acid detection research.
[0054] The term "crRNA" refers to a small guide RNA molecule that can guide targeting of specific nucleic acid molecules and activate the cleavage activity of Cas12a.
[0055] The term "ssDNA-FQ dual fluorescence reporter gene" refers to a certain length of single-stranded DNA (ssDNA), with fluorescent groups and quenching groups added to the bases at its 5' and 3' ends. Its role in the CRISPR detection system is that when ssDNA is non-specifically cut by Cas12a, the fluorescent group and the quenching group separate, and the quenching group releases the blocking effect on the fluorescent group. Under the condition of irradiation with light of a specific wavelength, the change in fluorescence intensity can be detected with the help of a fluorescent signal detection device.
[0056] The term "brucellosis" refers to brucellosis, a zoonotic systemic infectious disease caused by Brucella.
[0057] Sources and physical and chemical parameters of key test materials:
[0058] White Shark Bio: IPTG, TAE solution (50×), 5xSDS loading buffer;
[0059] Qingke Biotechnology: 50bp DNA Ladder, DH5α competent cells;
[0060] Weidi Biotechnology: BL21(DE3) competent cells;
[0061] Huiyan Bio: affinity chromatography medium Ni Focurose FF (IMAC);
[0062] Bio-Technology: pMD TM 18T Vector Cloning Kit;
[0063] Novozymes: 2×Taq PCR Master Mix, 2×ChamQ Blue Universal SYBR qPCR MasterMix;
[0064] TwistDx: Basic Kit;
[0065] NEB: HiScribe TM Quick T7 High Yield RNA Synthesis Kit;
[0066] Tianyi Huiyuan Biotechnology: primers used in the experiments, ssDNA-FQ reporter gene;
[0067] Combined test gene: The plasmid constructed with the conserved gene fragment of pathogenic bacteria used in the experiment.
[0068] Example 1 Prokaryotic expression, purification and screening of Gs12-7 endonuclease targeting Brucella BCSP31 gene with high activity crRNA
[0069] The plasmid carrying the Gs12-7 endonuclease sequence was transformed into E. coli DE3 and cultured to OD 600 The concentration of 0.6-0.8 was 0.5 mM IPTG was added and cultured at 16 ° C for 16 h, and purified by NI column affinity chromatography. The Brucella BCSP31 gene (M20404.1) and genome (AE008917.1, CP006961.1) sequences were downloaded from the NCBI database. The 666 bp conservative fragment sequence of the BCSP31 gene was inserted into the EcoRI / HindIII site of the pTOPO cloning vector and sent to the company for synthesis; for this region, 7 crRNAs were designed using CRISPR-offinder software (https: / / sourceforge.net / projects / crispr-offinder-v12 / ), and PAMs were TTTV, GTTV, CTTV, ATTV, etc., and two pairs of partial reverse complementary primers were designed for each crRNA (see Table 1).
[0070] Table 1. crRNA sequences and BCSP31 gene fragments
[0071]
[0072]
[0073] It should be noted that the sequence SEQ ID No.: 9-SEQ ID No.: 15 contains the base "U", which makes it impossible to edit it into an ST2.6 file. Therefore, this application changes the base "U" in the sequence SEQ ID No.: 9-SEQ ID No.: 15 to the base "T", but in fact the base "T" in SEQ ID No.: 9-SEQ ID No.: 15 represents the base "U".
[0074] The overlap method was used to connect the PCR amplification as the template for in vitro transcription of crRNA. The BCSP31 plasmid was transformed into Escherichia coli DH5α, and the Brucella BCSP31 gene plasmid was extracted and the concentration was measured and stored for later use. The experimental steps for detecting nucleic acids using CRISPR / Gs12-7 are as follows:
[0075] (1) Purification of Gs12-7: Escherichia coli DE3 strain carrying Gs12-7 plasmid was cultured to OD 6000.6-0.8, add 0.5mM IPTG and culture at 16℃ for 16h, collect bacteria at 12000rpm for 2min, resuspend with wet weight of bacteria: lysis buffer = 1:9, ultrasonic for 2min, centrifuge at 9000rpm for 30min, take the supernatant and combine it with NI column filler for 2h, wash with 10-15 column volumes of washing buffer, elute 1mL×10 times, retain samples of each step, and perform SDS polyacrylamide gel electrophoresis. (Lysate: 300mM NaCL, 2mM MgCL, 5mM HEPES, 20mM imidazole, 1mM DTT; washing buffer: 500mM NaCL, 10mM Tris, 30mM imidazole; eluent: 500mM NaCL, 10mM Tris, 300mM imidazole).
[0076] (2) In vitro transcription of crRNA: T7+scaffold was used as the upstream primer, BCSP-crRNA-TTTV-1-R, BCSP-crRNA-TTTV-2-R, BCSP-crRNA-TTTV-3-R, BCSP-crRNA-TTTV-4-R, BCSP-crRNA-CTTV-1-R, BCSP-crRNA-GTTV-1-R, BCSP-crRNA-ATTV-1-R, etc. were used as downstream primers (see Table 1), and the template for in vitro transcription of crRNA was amplified using overlapPCR technology. The experimental reaction system was 50 μL, including 25 μL of Taq PCR MasterMix (Novozyme), and 0.4 μM of upstream and downstream primers. The reaction conditions were: initial denaturation at 95°C for 3 min; then 95°C for 15 s, 60°C for 15 s, and 72°C for 10 s, for a total of 31 cycles, and finally 72°C for 5 min. The PCR product was recovered using an agarose gel DNA recovery kit (Novozyme). According to HiScribe TM The crRNAs were synthesized using the Quick T7 High Yield RNA Synthesis Kit (NEB) at 37°C for about 16 h. The transcribed sgRNAs were purified using the phenol-chloroform method, and the concentration was determined and then aliquoted and frozen at -80°C for long-term storage.
[0077] (3) Gs12-7 digestion reaction: In a 20 μL reaction system, add the crRNA purified in step 2 (0.5 μM), Gs12-7 (0.25 μM), BCSP31 plasmid (100 ng), ssDNA-reporter (ROX-N12-BHQ2) (20 μM), rCutSmart TMNEBbuffer. The negative control was set as no target gene plasmid, that is, no BCSP31 gene plasmid. The positive control was set as only adding ssDNA activator and corresponding crRNA reaction primers, such as BCSP-crRNA-TTTV-1-R, BCSP-crRNA-TTTV-2-R, BCSP-crRNA-TTTV-3-R, BCSP-crRNA-TTTV-4-R, BCSP-crRNA-CTTV-1-R, BCSP-crRNA-GTTV-1-R, BCSP-crRNA-ATTV-1-R and other alternative target genes. The reaction was carried out at 37℃ for 15min, and then terminated at 98℃ for 2min.
[0078] Measurement and results
[0079] Directly place the centrifuge tube containing the Gs12-7 enzyme digestion reaction solution prepared in step (3) in a blue light gel cutting instrument to detect the change in fluorescence intensity; or aspirate the liquid and add it to an ELISA plate and add 80 μL of sterile double distilled water, and place it on a multifunctional ELISA instrument (excitation light 576 nm, emission light 601 nm) to detect the fluorescence signal. Figure 3 , 4 As shown, the ssDNA reporter in Example 1 was used, and the fluorescence signal was detected by fluorescence visualization, indicating that it can be used for CRISPR / Gs12-7 nucleic acid detection experiments. Comparing the 7 crRNAs targeting the Brucella BCSP31 gene, under the condition that the plasmid of the BCSP31 gene was used as a template, the fluorescence signal of BCSP-crRNA-GTTV-1 was the strongest, indicating that this crRNA had the highest detection activity, so BCSP-crRNA-GTTV-1 was comprehensively screened for detection. Figure 2 As shown, the protein band of Gs12-7 endonuclease elution and concentration was relatively pure.
[0080] Example 2: Screening of RPA primer pairs for specific detection of Brucella BCSP31 gene using RPA-CRISPR / Gs12-7 technology
[0081] RPA primers for the visual detection of Brucella based on RPA and CRISPR / Gs12-7 technology were screened. According to the RPA primer design principles, three pairs of RPA primers were designed for the crRNA with the highest detection activity: BCSP-crRNA-GTTV-1 (see Table 2).
[0082] Table 2: Primer pairs for RPA amplification
[0083]
[0084] Using the Brucella BCSP31 gene plasmid as a template, CRISPR / Gs12-7 nucleic acid fluorescence visualization detection was performed after RPA amplification. The experimental process is as follows:
[0085] (1) RPA amplification of BCSP31 gene fragment: The plasmid of Brucella BCSP31 gene was diluted to 6.02×10 4 copies / μl, 6.02×10 1 copies / μl, 6.02×10 0 The amplification system was 50 μL, with RNA of BCSP31 gene at different dilutions as template, BCSP target RPA-F1 / BCSP target RPA-R1, BCSP target RPA-F2 / BCSP target RPA-R2, BCSP target RPA-F3 / BCSP target RPA-R3 as primers, and the negative control was set as no Brucella BCSP31 gene plasmid template. One basic reaction tube (Twist Dx), 0.5μM each of upstream and downstream primers, 29.5μL of buffer, 2.5μL of MgSO4, the above dilutions correspond to the BCSP31 gene plasmid and negative control, and add nuclease-free water to 50μL. Amplify at 39℃ for 20min and inactivate at 56℃ for 10min. After the reaction, take 10μL of the amplified product and perform electrophoresis on a 2% agarose gel for identification.
[0086] (2) In vitro transcription of crRNA: Using T7+scaffold as the upstream primer and BCSP-crRNA-GTTV-1-R as the downstream primer (see Table 1 for the specific sequence), overlap PCR technology was used to amplify the template for in vitro transcription of crRNA. The experimental reaction system was 50 μL, including 25 μL of Taq PCR Master Mix (Novozymes) and 0.4 μM of each upstream and downstream primer. The reaction conditions were: initial denaturation at 95°C for 3 min; followed by 95°C for 15 s, 60°C for 15 s, and 72°C for 10 s, for a total of 31 cycles, and finally extension at 72°C for 5 min. The PCR product was recovered using an agarose gel DNA recovery kit (Novozymes). According to HiScribe TM The crRNAs were synthesized using the Quick T7 High Yield RNA Synthesis Kit (NEB) at 37°C for about 16 h. The transcribed sgRNAs were purified using the phenol-chloroform method, and the concentration was determined and then aliquoted and frozen at -80°C for long-term storage.
[0087] (3) Gs12-7 digestion reaction: In a 20 μL reaction system, add the crRNA purified in step 2 (0.5 μM), Gs12-7 (0.25 μM), 2.5 μL of the RPA amplification product in step 1, ssDNA-reporter (ROX-N12-BHQ2) (20 μM), and rCutSmart NEBbuffer. Incubate at 37°C for 15 min, then terminate the reaction at 98°C for 2 min.
[0088] Result detection and judgment
[0089] Directly place the centrifuge tube containing the reaction solution in a blue light gel cutting instrument to detect changes in fluorescence intensity, and compare the changes in the intensity of the fluorescence visualization detection signal after amplification with different primers; or aspirate the liquid and add it to the ELISA plate and add 80 μL of sterile double distilled water, and use a multifunctional ELISA reader (excitation light 576 nm, emission light 601 nm) to read the value; in this way, the amplification efficiency of the RPA amplification primer can be judged.
[0090] result
[0091] The RPA amplification products were detected by gel electrophoresis. It can be seen that there is no significant difference in the minimum sensitivity of the three primers for the detection of Brucella BCSP31 gene by RPA amplification gel electrophoresis ( Figure 5 ); After the RPA product was digested with Gs12-7, it was detected by a blue light gel cutting instrument or a UV gel imaging system. The lowest sensitivity was PCR tube No. 10, which corresponds to a template concentration of 6.02×10 1 Copies / μl ( Figure 6 ). Further, the Gs12-7 enzyme digestion reaction solution was placed in a multifunctional microplate reader. Figure 7 It can be seen that Figure 6 The results were the same, and the detection sensitivity could reach 6.02×10 1 Therefore, the fluorescence signal of BCSP target RPA-F3 / BCSP target RPA-R3 was the strongest, indicating that the amplification efficiency of this pair of RPA primers was the highest.
[0092] Example 3: Evaluation of the sensitivity of RPA-CRISPR / Gs12-7 technology in detecting the Brucella BCSP31 gene
[0093] To evaluate the sensitivity of the CRISPR / Gs12-7 technology-based visual detection method for Brucella, the Brucella BCSP31 gene plasmid was diluted into different copy numbers as a template, and then amplified by RPA and then subjected to CRISPR / Gs12-7 nucleic acid fluorescence visualization detection and multifunctional microplate reader detection. The experimental process is as follows:
[0094] (1) RPA amplification sensitivity test: The plasmid of Brucella BCSP31 gene was diluted to 6.02×10 9 copies / μl, 6.02×10 8 copies / μl, 6.02×10 7 copies / μl, 6.02×10 6 copies / μl, 6.02×10 5 copies / μl, 6.02×10 4 copies / μl, 6.02×10 3 copies / μl, 6.02×10 2 copies / μl, 6.02×10 1 copies / μl, 6.02×10 0 copies / μl, 6.02×10 -1 The plasmid of BCSP31 gene with different dilution multiples was used as template and amplified with BCSP target RPA-F3 / BCSP target RPA-R3 (nucleotide sequence is shown in Table 2); the amplification system was 50 μL, wherein One basic reaction tube (Twist Dx), 0.5μM each of upstream and downstream primers, 29.5μL of buffer, 2.5μL of MgSO4, 1μL of BCSP31 gene plasmid corresponding to the above dilution, and make up to 50μL with nuclease-free water. Amplify at 39℃ for 20min and inactivate at 56℃ for 10min. After the reaction, take 10μL of the amplified product and perform electrophoresis on 2% agarose gel for identification.
[0095] (2) Preparation of crRNA by in vitro transcription: T7+scaffold was used as the upstream primer and BCSP-crRNA-GTTV-1-R was used as the downstream primer (nucleotide sequence is shown in Table 1), and the template for in vitro transcription of crRNA was amplified by overlapPCR technology. The experimental reaction system was 50 μL, including 25 μL of Taq PCR Master Mix (Novagen), and 0.4 μM of upstream and downstream primers. The reaction conditions were: initial denaturation at 95°C for 3 min; then 95°C for 15 s, 60°C for 15 s, and 72°C for 10 s, for a total of 31 cycles, and finally extension at 72°C for 5 min. The PCR product was recovered using an agarose gel DNA recovery kit (Novagen). crRNAs were synthesized according to the HiScribeTM QuickT7High Yield RNA Synthesis Kit (NEB), and the reaction conditions were: 37°C for about 16 h. The transcribed sgRNAs were purified by the phenol-chloroform method, and after the concentration was determined, they were aliquoted and frozen at -80°C for long-term storage.
[0096] (3) Gs12-7 digestion reaction: In a 20 μL reaction system, add the crRNA purified in step 2 (0.5 μM), Gs12-7 (0.25 μM), 2.5 μL of the RPA amplification product in step 1, ssDNA-reporter (ROX-N12-BHQ2) (20 μM), and rCutSmart NEB buffer. Incubate at 37°C for 15 min, then terminate the reaction at 98°C for 2 min.
[0097] Result detection and judgment
[0098] Directly place the centrifuge tube containing the reaction solution in a blue light gel cutting instrument to detect changes in fluorescence intensity; compare the changes in the intensity of the fluorescence visualization detection signal after amplification using different copy templates; or use a multifunctional microplate reader (excitation light 576nm, emission light 601nm) to read the numerical value; this is used to determine the sensitivity of nucleic acid detection.
[0099] result
[0100] The RPA amplification product was detected by gel electrophoresis. It can be seen that the lowest sensitivity of RPA amplification gel electrophoresis for Brucella BCSP31 gene detection is lane 8 (based on the figure, the 8th lane from left to right), corresponding to the dilution concentration of BCSP31 gene plasmid template of 6.02×10 3 Copies / μl ( Figure 8 ); Brucella BCSP31 gene plasmid was amplified by RPA, and the RPA product was digested with Gs12-7 and detected by blue light gel cutting instrument or UV gel imaging system. The lowest sensitivity was PCR tube No. 9 (based on the figure, PCR tube No. 9 from left to right), which corresponds to a template dilution concentration of 6.02×10 1 Copies / μl ( Fig. 9 ). Further, the Gs12-7 enzyme digestion reaction solution was placed in a multifunctional microplate reader and it was observed that Fig. 9 The results were the same, and the detection sensitivity could reach 6.02×10 1 Copies / μl ( Fig.10 ).
[0101] Example 4: Evaluation of the specificity of RPA-CRISPR / Gs12-7 technology for detecting the Brucella BCSP31 gene
[0102] Furthermore, the specificity of the CRISPR / Gs12-7 technology-based visual detection method for Brucella was evaluated. The main purpose was to test whether it could distinguish other pathogens that sheep are currently susceptible to. The designed experimental process is as follows:
[0103] (1) Construction of plasmids of DNA fragments of conserved regions of the genomes of different pathogenic bacteria: Brucella BCSP31 gene (M20404.1) was downloaded from the NCBI database and fragments were inserted into the EcoRI / HindIII site of the pTOPO cloning vector, Yersinia ail gene (M29945.1), Francisella tularensis fopA gene (CP009607.1), and Salmonella invA gene (M90846.1), etc., and fragments were inserted into the Sma I site of the PUC57 cloning vector, which was synthesized by Wuhan Hece Gene Technology Co., Ltd.; primers were designed for the Escherichia coli 23S ribosomal gene (NR_076322.1), and PCR amplification was performed using Escherichia coli (DH5α) (Qingke) as a template (Novozyme), and the PCR product was recovered (Novozyme), and then the PMD-18T vector (TAKARA) was used for ligation and transformation, and the plasmid was extracted (omega), and the concentration was measured and frozen at -20°C for later use.
[0104] >PUC57-ail (Yersinia ail gene fragment)
[0105] GCAAGTAAGACGTCAATGGCATACGGGGCAGGGGTGCAATTCAACCCACTTCCAAATTTTGTCATTGACGCTTCATATGAATACTCCAAACTCGATAGCATAAAAGTTGGCACCTGGATGCTTGGTGCAGGGTATCGATTCTAATCATCTCAGATAGTGAAAACCCACCTGAGTGAAGTGAACCCCATTT ATTGGACACTTTTCCTGGCGGTTGACATGGCCTGATTTCGGTACTGCACCGGACTCAGGCCGTTTAATTTTACTTTGATCCTTTCGTTGTTGTAGTAATGGATATACTCATCCACCGCTTTTTCAGTTGTTCTACATCTTCGTATTTTTCATTGTGCCAGCATTCAGTCTTCAGCAGACCAAAAAAGTT
[0106] >PUC57-fopA (Franciscoidea tularensis fopA gene fragment)
[0107] AATAATTTCATTGCTCCTTTTGCAAATACTTATAGCGCTTTGACTAACAAGGACAATACTTGGGGTCCTCAAGATAGAACTGGCCAGTGGTACTTAGGTGTAGATGCTAACGGTCTAGCTGGAACTCCTAACTCTCCATCAGGTGCTGGTGCTAACTTCACAATCGGTTATAACATCAATAAATACTTCGCTGTACAGTACAACCAATTAGTTGGTAGAGTATTTGCTGGTTTAGGTGAAGGTGTTGTAAACTTTAGTAATAATACTATGTTTACTCCATATGCTGCAGGTGGTGCTGGTTGGGCAAATCTAGCAGGTCAAGCAACAGGTGCT
[0108] >PUC57-invA (Salmonella invA gene fragment)
[0109] GCCGATGCCGGTGAAATTATCGCCACGTTCGGGCAATTCGTTATTGGCGATAGCCTGGCGGTGGGTTTTGTTGTCTTCTCTATTGTCACCGTGGTCCAGTTTATCGTTATTACCAAAGGTTCAGAACGTGTCGCGGAAGTCGCGGCCCGATTTTCTCTGGATGGTATGCCCGGTAAACAGATGAGTATTGATGCCGATTTGAAGGCCGGTATTATTGATGCGGATGCCGCGCGCGAACGGCGAAGCGTACTGGAAAGGGAAAGCCAGCTTTACGGTTCCTTTGACGGTGCGATGAAGTTTATCAAAGGTGACGCTATTGCCGGCATCATTATTATCTTTGTGAACTTTATTGGCGGTATT
[0110] >PMD-18T-23S (E. coli 23S ribosomal gene fragment)
[0111] AGTGGAAGCGTCTGGAAAGGCGCGCGATACAGGGTGACAGCCCCGTACACAAAAATGCACATGCTGTGAGCTCGATGAGTAGGGCGGGACACGTGGTATCCTGTCTGAATATGGGGGGACCATCCTCCAA GGCTAAATACTCCTGACTGACCGATAGTGAACCAGTACCGTGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGTGAAAAAGAACCTGAAACCGTGTACGTACAAGCAGTGGGAGCACAGAGCAATCTGT GTGACTGCGTACCTTTTGTATAATGGGTCAGCGACTTATATTCTGTAGCAAGGTTAACCGAATAGGGGAGCCGAAGGGAAACCGAGTCTTAACTGGGCGTTAAGTTGCAGGGTATAGACCCGAAACCCGG TGATCTAGCCATGGGCAGGTTGAAGGTTGGGTAACACTAACTGGAGGACCGAACCGACTAATGTTGAAAAATTAGCGGATGACTTGTGGCTGGGGGTGAAAGGCCAATCAAACCGGGAGATAGCTGGTTCT
[0112] (2) RPA amplification specificity detection: The plasmids carrying the Brucella BCSP31 gene, Yersinia ail gene fragment, Francisella tularensis fopA gene fragment, Salmonella invA gene fragment, and Escherichia coli 23S ribosomal gene fragment in step 1 were used as templates, and amplified using BCSP target RPA-F3 / BCSP target RPA-R3 (nucleotide sequences are shown in Table 2); the amplification system was 50 μL, wherein One basic reaction tube (Twist Dx), 0.5μM each of upstream and downstream primers, 29.5μL of buffer, 2.5μL of MgSO4, 1μL of the corresponding plasmid, and add nuclease-free water to 50μL. Amplify at 39℃ for 20min, and inactivate at 56℃ for 10min. After the reaction, take 10μL of the amplified product and perform electrophoresis on 2% agarose gel for identification.
[0113] (3) Preparation of crRNA by in vitro transcription: Using T7+scaffold as the upstream primer and BCSP-crRNA-GTTV-1-R as the downstream primer (nucleotide sequence see Table 1), overlapPCR technology was used to amplify the template for in vitro transcription of crRNA. The experimental reaction system was 50 μL, including 25 μL of Taq PCR Master Mix (Novozymes) and 0.4 μM of each upstream and downstream primer. The reaction conditions were: initial denaturation at 95°C for 3 minutes; followed by 95°C for 15 seconds, 60°C for 15 seconds, and 72°C for 10 seconds, for a total of 31 cycles, and finally extension at 72°C for 5 minutes. The PCR product was recovered using an agarose gel DNA recovery kit (Novozymes). According to HiScribe TM The crRNAs were synthesized using the Quick T7 High Yield RNA Synthesis Kit (NEB) at 37°C for about 16 h. The transcribed sgRNAs were purified using the phenol-chloroform method, and the concentration was determined and then aliquoted and frozen at -80°C for long-term storage.
[0114] (4) Gs12-7 digestion reaction: In a 20 μL reaction system, add the crRNA purified in step 3 (0.5 μM), Gs12-7 (0.25 μM), 2.5 μL of the RPA amplification product in step 2, ssDNA-reporter (ROX-N12-BHQ2) (20 μM), and rCutSmartNEB buffer. Incubate at 37°C for 15 min, then terminate the reaction at 98°C for 2 min.
[0115] Result detection and judgment
[0116] Directly place the centrifuge tube containing the reaction solution in a blue light gel cutting instrument to detect changes in fluorescence intensity, and compare the changes in the intensity of the fluorescence visualization detection signal after amplification using the conserved gene plasmids of different pathogenic bacteria as templates; or aspirate the liquid and add it to the ELISA plate and add 80 μL of sterile double distilled water, and place it on a multifunctional ELISA instrument (excitation light 576 nm, emission light 601 nm) to detect the fluorescence signal to determine the specificity of nucleic acid detection.
[0117] result
[0118] By detecting the RPA amplification products through gel electrophoresis, it can be seen that only lane 2 (the second lane from left to right based on the attached figure), i.e. the Brucella BCSP31 gene plasmid as the template group, has a bright band, and the other template lanes have no obvious bright bands ( Fig.11 ); Through the detection of blue light gel cutting instrument or UV gel imaging system, only the Brucella BCSP31 gene plasmid as template group showed obvious fluorescence signal, while the other groups had no obvious fluorescence signal ( Fig.12). Further, the Gs12-7 enzyme digestion reaction solution was added with 80 μL of sterile double distilled water and placed in a multifunctional microplate reader ( Fig.13 ),and Fig.12 The results were the same. Only the Brucella BCSP31 gene plasmid as the template group showed an obvious fluorescent signal, that is, only the Brucella BCSP31 gene could be detected, and there was no cross-reaction with the other four susceptible pathogens to which sheep were susceptible, resulting in false positive results. This shows that the specificity of detecting the Brucella BCSP31 gene based on the combination of RPA and CRISPR / Gs12-7 is high.
[0119] Example 5: Evaluation of the accuracy of RPA-CRISPR / Gs12-7 technology in detecting Brucella simulated clinical samples
[0120] Furthermore, the accuracy of the CRISPR / Gs12-7-based visual detection method for Brucella was evaluated. The main purpose was to test its accuracy in the standardized detection of Brucella infection in sheep. Figure 1 As shown, the designed experimental process is as follows:
[0121] Table 3: qPCR primer pairs
[0122] Primer name Sequence Listing Primer sequence 5'-3' Remark BCSP-qPCR-1F SEQ ID No.:23 ATCCGACGCAAAACCGTTTC qPCR primers BCSP-qPCR-1R SEQ ID No.:24 CTTTGCCGGTCGTGCATTTC qPCR primers
[0123] (1) Preparation of simulated clinical samples of sheep infected with Brucella: The plasmid containing the Brucella BCSP31 gene fragment was transformed into Escherichia coli (DH5α) (Qingke), and a single clone was selected for overnight culture. 1 μL, 2 μL, 5 μL, 10 μL, 20 μL, and 40 μL of the bacterial solution were mixed with 100 μL of sheep blood, and 20 μL of crude extract was added. The negative control was set as follows: the bacterial solution was replaced with sterile double distilled water, first heated at 65°C for 5 min, then heated at 95°C for 5 min, centrifuged at 12000 rpm for 2 min, and the supernatant was frozen at -20°C for later use.
[0124] (2) Preparation of crRNA by in vitro transcription: T7+scaffold was used as the upstream primer and BCSP-crRNA-GTTV-1-R was used as the downstream primer (nucleotide sequence is shown in Table 1), and the template for in vitro transcription of crRNA was amplified by overlapPCR technology. The experimental reaction system was 50 μL, including 25 μL of Taq PCR Master Mix (Novagen), and 0.4 μM of upstream and downstream primers. The reaction conditions were: initial denaturation at 95°C for 3 min; then 95°C for 15 s, 60°C for 15 s, and 72°C for 10 s, for a total of 31 cycles, and finally extension at 72°C for 5 min. The PCR product was recovered using an agarose gel DNA recovery kit (Novagen). crRNAs were synthesized according to the HiScribeTM QuickT7High Yield RNA Synthesis Kit (NEB), and the reaction conditions were: 37°C for about 16 h. The transcribed sgRNAs were purified by the phenol-chloroform method, and after the concentration was determined, they were aliquoted and frozen at -80°C for long-term storage.
[0125] (3) Accuracy of RPA combined with CRISPR / Gs12-7 in detecting Brucella: The genomic supernatant extracted in step 1 was shuffled and numbered (S1-S12) as a template and amplified with BCSP target RPA-F3 / BCSP target RPA-R3 (nucleotide sequence see Table 2); the amplification system was 50 μL, where One basic reaction tube (Twist Dx), 0.5μM each of upstream and downstream primers, 29.5μL of buffer, 2.5μL of MgSO4, 2.5μL of the corresponding supernatant, and make up to 50μL with nuclease-free water. Amplify at 39℃ for 20min and inactivate at 56℃ for 10min. Then use Gs12-7 for enzyme digestion reaction: in a 20μL reaction system, add crRNA purified in step 2 (0.5μM), Gs12-7 (0.25μM), 2.5μL of RPA amplification product, ssDNA-reporter (ROX-N12-BHQ2) (20μM), and rCutSmart NEB buffer. React at 37℃ for 15min, then terminate the reaction at 98℃ for 2min.
[0126] (4) qPCR sensitivity and simulated clinical sample detection: The plasmid of Brucella BCSP31 was diluted to 6.02×10 9 copies / μl, 6.02×10 8 copies / μl, 6.02×10 7 copies / μl, 6.02×10 6 copies / μl, 6.02×10 5 copies / μl, 6.02×104 copies / μl, 6.02×10 3 copies / μl, 6.02×10 2 copies / μl, 6.02×10 1 qPCR detection was performed using the plasmid of BCSP31 gene at different dilution multiples and the genomic supernatant (S1-S12) extracted in step 1 as templates and BCSP-qPCR-1F and BCSP-qPCR-1R as primers (nucleotide sequences are shown in Table 3); the system was operated on Bio-Rad CFX96 TM The specific steps are as follows: the reaction system is 20 μL, wherein SYBR High-Sensitivity qPCR Super Mix 10 μL, upstream and downstream primers 0.4 μM each, template 1 μL. The reaction procedure is: first 95°C for 1 min, then 95°C for 20 s, 65°C for 45 s for 40 cycles.
[0127] Result detection and judgment
[0128] Directly place the centrifuge tube containing the reaction solution in a blue light gel cutting instrument to detect changes in fluorescence intensity, and compare the changes in the intensity of the fluorescence visualization detection signal after using different simulated sample supernatants as templates for amplification; or aspirate the liquid and add it to the ELISA plate and add 80 μL of sterile double distilled water, and place it on a multifunctional ELISA instrument (excitation light 576 nm, emission light 601 nm) to detect the fluorescence signal, and compare the fluorescence visualization detection signal with the qPCR result to determine the accuracy.
[0129] result
[0130] Through the detection of blue light gel cutting instrument or UV gel imaging system, sample tubes S4, S5, S6, S9, S10, S11 showed obvious fluorescence signals, while the other groups had no obvious fluorescence signals ( Fig.14 ). Further, the Gs12-7 enzyme digestion reaction solution was placed in a multifunctional microplate reader ( Fig.15 ),and Fig.14 The results were the same, and obvious fluorescence signals appeared in sample tubes S4, S5, S6, S9, S10, and S11, which were highly consistent with the qPCR results ( Fig.16), that is, only the Brucella BCSP31 gene can be detected, and the negative simulated clinical samples without the Brucella BCSP31 gene plasmid will not show fluorescent signals, resulting in false positive results, indicating that the accuracy of detecting the Brucella BCSP31 gene based on the combination of RPA and CRISPR / Gs12-7 is strong. It is proved that the visualization detection technology of Brucella based on the RPA-CRISPR / Gs12-7 system mediation developed by the present invention has certain practical significance in clinical detection.
[0131] In short, after extensive and in-depth research, the present invention has developed a visualization detection technology for Brucella nucleic acid based on the RPA-CRISPR / Gs12-7 system, which is a method that can be used for fluorescent visualization detection of Brucella nucleic acid. By screening crRNA and RPA primers, a new strategy for real-time, rapid, sensitive and specific detection of brucellosis has been developed, with sensitivity and specificity comparable to the qPCR "gold standard", and combined with the quantitative identification fluorescence intensity method of the multifunctional microplate reader, the reaction and result interpretation are integrated, and the accuracy of the naked eye identification method is enhanced.
[0132] The specific raw materials not described in the present invention are all existing materials and can be directly purchased from the market.
[0133] The above are only preferred embodiments of the present invention and are not intended to limit the protection scope of the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A Brucella CRISPR nucleic acid visualization detection kit, characterized in that, It comprises an RPA primer, wherein the RPA primer comprises F and R, wherein the nucleotide sequence of F is shown as SEQ ID NO.21; and the nucleotide sequence of R is shown as SEQ ID NO.
22.
2. The kit according to claim 1, characterized in that It also includes crRNA, the nucleotide sequence of which is shown in SEQ ID NO.
14.
3. The kit according to claim 2, characterized in that The crRNA is used to target the BCSP31 gene, and the nucleotide sequence of the BCSP31 is shown in SEQ ID NO.
16.
4. according to the application of any one of the test kits of claim 1-3 in detecting Brucella for non-diagnosis purpose.
5. A method for detecting Brucella using a test kit according to any one of claims 1 to 3 for non-diagnostic purposes, characterized in that: The following steps are involved: S1. Obtain Brucella nucleic acid template; S2, amplifying the Brucella nucleic acid template to obtain an amplified product; S3, subjecting the amplified product to a restriction digestion reaction with the homologous protein Gs12-7 of Cas12a to obtain a restriction digestion product; S4. Detect the enzyme cleavage product under blue light, ultraviolet light and microplate reader; when there is a fluorescent signal under the blue light and ultraviolet light, and the fluorescence value detected by the microplate reader is greater than 1488, the test result is positive; when there is no fluorescent signal under the blue light and ultraviolet light, and the fluorescence value detected by the microplate reader is less than 1488, the test result is negative.
6. The method according to claim 5, characterized in that In step S1, the specific steps of obtaining the Brucella nucleic acid template are: mixing the sheep blood and the crude extract, heating them, centrifuging them, and taking the supernatant for storage.
7. The method according to claim 6, characterized in that The heating conditions were: first heating at 65°C for 5 min, and then heating at 95°C for 5 min.
8. The method according to claim 6, characterized in that The centrifugation conditions were a rotation speed of 12000 rpm and a centrifugation time of 2 min.
9. The method according to claim 5, characterized in that In step S2, the Brucella nucleic acid template is amplified using an amplification system, the volume of the amplification system is 50 μL, and the amplification system comprises: A basic reaction tube (Twist Dx), 29.5 μL Buffer, 2.5 μL MgSO4, 2.4 μL primer F, 2.4 μL primer R, 2.5 μL Brucella nucleic acid template, and add nuclease-free water to 50 μL.
10. The method according to claim 5, characterized in that In step S3, the reaction system of the enzyme digestion reaction includes: 1 μM purified crRNA targeting Brucella nucleic acid gene, 2.5 μL of the amplified product, 0.5 μM Cas12a, 1 μM ssDNA-FQ reporter (ROX-N12-BHQ2), 2 μL 10xNEB rCutSmart TM Buffer, make up the reaction system to 20 μL with nuclease-free water.
